Strategies for Managing Suboptimal Response to JAK Inhibitors in Alopecia Areata
August 2025
in “
Acta Dermato Venereologica
”
Research cited in this study
8 / 8 resultsresearch Combination Oral Minoxidil and Baricitinib Treatment of Alopecia Areata
research The Role of Minoxidil in the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis
This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.
research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata
This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.
research Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response
This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.
research The Role of Micronutrients in Alopecia Areata: A Review
This review found that patients with alopecia areata may have lower levels of vitamin D, zinc, and folate, but conflicting evidence precludes definitive clinical recommendations for micronutrient supplementation.
Related Research
1 / 1 results
research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child
This case report describes a 6-year-old child with twenty nail dystrophy and alopecia areata of the scalp.